Cardiovascular disease, cerebrovascular disease, neurological dysfunction, maintenance hemodialysis, antithrombin III, rhTM, sivelestat, cephalosporin (1st, 2nd, and 4th generation), clindamycin, minocycline, anti-MRSA drugs, number of IMV weaning days, NPPV, NHF oxygen therapy, oxygen therapy, use of polymyxin B-immobilized fiber column, and ICU admission rate were excluded from the variables because there were no patients to include. The gene discussed is SERPINC1; the disease is cardiovascular disorder.